Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
about
Endostatin improves cancer-associated systemic syndrome in a lung cancer modelNumerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.
P2860
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Systemic administration of bev ...... num pre-treated ovarian cancer
@ast
Systemic administration of bev ...... num pre-treated ovarian cancer
@en
type
label
Systemic administration of bev ...... num pre-treated ovarian cancer
@ast
Systemic administration of bev ...... num pre-treated ovarian cancer
@en
prefLabel
Systemic administration of bev ...... num pre-treated ovarian cancer
@ast
Systemic administration of bev ...... num pre-treated ovarian cancer
@en
P2093
P2860
P356
P1433
P1476
Systemic administration of bev ...... num pre-treated ovarian cancer
@en
P2093
Anne Kathrin Volkmer
Anne Kathrin Welter
Daniel T Rein
Dirk Bauerschlag
Jens Volkmer
Markus C Fleisch
Martina Breidenbach
Thomas Schöndorf
Wolfgang Janni
P2860
P304
P356
10.3892/OL.2012.553
P50
P577
2012-01-03T00:00:00Z